Blog

Home  /  Outputs   /  EUnetHTA Joint Action 2 (2012-15)   /  Joint Assessment on sorafenib (Nexavar®) and its use for the treatment of progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma refractory to radioactive iodine

Joint Assessment on sorafenib (Nexavar®) and its use for the treatment of progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma refractory to radioactive iodine

The purpose of the assessment is to evaluate sorafenib Nexavar® and its use as a treatment of thyroid carcinoma

Final version of the assessment was published in March 2015

Below is the documentation provided by the Joint Assessment authoring team:

 

Sorafenib for the treatment of thyroid carcinoma_Rapid REA_Final_Mar 2015_0